Prostate cancer Cancer Malignant neoplasm of prostate
Conditions
Interventions
Digital images of histopathology slides prepared from prostate core needle biopsy tissue for primary diagnosis are viewed by specialist histopathologists according to the standard diagnostic pathway f
Sponsors
University of Oxford
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: All patients undergoing prostate biopsy for suspected prostate cancer
Exclusion criteria
Exclusion criteria: 1. Patients who have opted out of clinical care via the existing 'consent to examination or treatment policy' 2. Non-prostate biopsy tissue
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immediate changes to diagnostic reports of prostate biopsy cases and the corresponding immediate changes in patients' clinical management due to the use of Paige Prostate assistance, as measured by cancer/ASAP identification, Gleason grade 4 identification, tumour burden including length, number of involved cores, treatment pathway recommendation as determined by a multidisciplinary team (MDT). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Impact of Paige Prostate on resource utilisation, as measured by time and tests required for pathologists to review prostate biopsy cases and make clinical recommendations at MDT, and as measured by labour landscape in terms of staff and workloads. Comparison of resource utilisation across two separate consecutive cohorts, one without Paige Prostate, and one after Paige Prostate deployment. 2. Impact of Paige Prostate on patient management, as modeled using health economics and current patient pathways, their co-morbidities and their costs, and the diagnostic discrepancies comparing unassisted and assisted diagnoses over the lifetime of a prostate cancer patient receiving biopsy. 3. Impact of Paige Prostate on the experiences of histopathologists, urologists and patients, as measured by survey and qualitative methods on prostate biopsy diagnosis and treatment selection challenges, comparing standard of care immediate experience at baseline to experience ascertained as pathologists go through the learning curve of adopting AI over the course of this study. | — |
Countries
England, United Kingdom
Contacts
Public ContactMonica Dolton
Outcome results
None listed